Gemcitabine News
Taxotere® plus Gemzar® Provides Anticancer Responses in Metastatic Soft-Tissue Sarcomas
According to an article recently published in the International Journal of Cancer, the combination consisting of chemotherapy agents Taxotere® (docetaxel) and Gemzar® (gemcitabine) provides anticancer responses and may improve...
Gemzar® Delays Recurrences in Early Pancreatic Cancer
According to an article recently published in the Journal of the American Medical Association, treatment with Gemzar® (gemcitabine) following the surgical removal of pancreatic cancer delays the time to a cancer recurrence.
Talabostat plus Gemzar® Shows Potential in Treatment of Advanced Pancreatic Cancer
According to results from a press release from Point Therapeutics, the combination of the investigative agent talabostat plus the chemotherapy agent Gemzar® (gemcitabine) may be a potentially effective treatment for metastatic...
Low Hematologic Toxicity Rate for Gemzar® and Ellence® in Advanced NSCLC
Researchers from Italy have reported that the combination of Gemzar (gemcitabine) and Ellence (oxaliplatin) (GEMOX) has a good toxicity profile and equivalent effectiveness to other non-Platinol® (cisplatin)-based regimens for...
Further Evidence for Activity of Gemzar® and Ellence® in Advanced NSCLC
Researchers from Greece have reported palliative benefit in over 40% of patients with non-small cell lung cancer (NSCLC) who have failed platinum and taxane therapies with a regimen of Gemzar (gemcitabine) and Ellence...